| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2009-09-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2011-04-06^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2305274-A1 |
| titleOfInvention |
Use of WNT stimulators for treating demyelinating diseases |
| abstract |
The present invention relates to the use of an effective amount of a Wnt, a Wnt-like substance, and/or a compound stimulating the Wnt signalling pathway for the preparation of a pharmaceutical composition intended to reduce the extent or degree of nerve demyelination in the central and peripheric nervous system of an individual suffering from a demyelinating disorder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111107110-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019020374-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3574019-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11343005-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111107110-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-201700084299-A1 |
| priorityDate |
2009-09-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |